ALMS News

Alumis to Present at the Leerink Partners Global Healthcare Conference

Alumis to Participate in Upcoming February Investor Conferences

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Alumis Announces Proposed Public Offering of Common Stock

Morning Market Brief: Breakthrough Biology Meets Scalable Platforms as Innovators Surge into Focus

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Alumis to Participate in Upcoming November Investor Conferences